Quarterly Activities/Appendix 4C Cash Flow Report

• Recruitment momentum in Pivotal (Validation) Trial for the emu™
• Continuous Innovation Study delivering valuable insights
• First Responder device progressed with ethics approval obtained

EMVision Medical Devices continued the expanded execution of its Pivotal (Validation) Trial for the emu™, designed to support regulatory submission and market entry. Recruitment is set to accelerate with the activation of additional trial sites, including UCLA Health and Mt Sinai West. The Continuous Innovation Study, operating in parallel, continues to deliver valuable insights for ongoing algorithm and feature development. The company also achieved significant milestones in its First Responder program, with ethics approval obtained for the Royal Flying Doctor Service (RFDS) Aeromedical Study and the Mobile Stroke Unit (MSU) Workflow Study in Melbourne, with the MSU study commencing recruitment. EMVision was awarded a $3 million Cooperative Research Centres Projects (CRC-P) non-dilutive grant to evaluate the impact of an expedited stroke care model enabled by a telehealth-integrated emu™ device in regional hospitals. The company successfully raised $12.0 million via a placement, with strong support from new and existing institutional and sophisticated investors. EMVision is well-funded with cash reserves of $18.35 million as at 30 September 2025, with additional non-dilutive funding available from current grant programs and the company's FY25 R&D tax incentive rebate.

The company is well-funded with cash reserves of $18.35 million as at 30 September 2025, with additional non-dilutive funding available from current grant programs ($7.4 million) and the company's FY25 R&D tax incentive rebate.

Over the coming quarter, EMVision's focus will remain on accelerating patient recruitment in the emu™ Pivotal (Validation) Trial, advancing the First Responder pre-hospital studies, participating in industry events, commencing preparations for the regional benefits study, continuing to build its go-to-market strategy, and maintaining financial discipline while executing on strategic milestones.